Ascendis Pharma swings to Q2 profit on revenue doubling, PRV sale
ASND•Outlook
- Company expects EMA decision on YUVIWEL in Q4 2026
- Ascendis plans to initiate Phase 3 trial of TransCon CNP for hypochondroplasia in H2 2026
- Company expects to start Phase 3 trial of TransCon CNP + TransCon hGH in pediatric achondroplasia in Q4 2026
Overview
- Denmark-based biopharma's Q2 product revenue rose 105% yr/yr, driven by TransCon product demand
- Company posted net profit of €207 mln, reversing prior-year loss
- Growth supported by YORVIPATH sales and €158 mln PRV sale
Result drivers
- YORVIPATH demand - Co said Q2 revenue growth was driven by consistent new patient demand for YORVIPATH in the U.S. and expansion in over 35 countries
- PRV sale - Q2 operating profit benefited from €158 mln in cash from sale of Rare Pediatric Disease Priority Review Voucher
- Commercial expansion - Higher selling, general, and administrative expenses due to continued impact from commercial expansion, including global launch activities
Key details and valuation
Related News
Bed Bath & Beyond, Inc. Appoints Jill Windrum As Chief Accounting Officer And Deputy Chief Financial Officer
BBBY•
PLDT 1H FY26 net income falls 6% to PHP 16.53 billion; revenue rises 2% to PHP 112.01 billion
PHI•
